2. Search Result
Search Result
Results for "

Protein arginine methyltransferase 5

" in MedChemExpress (MCE) Product Catalog:

23

阻害剤およびアゴニスト

1

ペプチド

1

組換えタンパク質

Targets Recommended:
製品番号 製品名 Target 研究分野 構造式
  • HY-101563
    GSK3326595
    Maximum Cited Publications
    31 Publications Verification

    EPZ015938

    		 Histone Methyltransferase SARS-CoV MDM-2/p53 CDK Apoptosis Infection Cancer
    GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .
    GSK3326595
  • HY-101564
    Onametostat
    5+ Cited Publications

    JNJ-64619178

    		 Histone Methyltransferase Cancer
    Onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.14 nM. Onametostat has potent activity in lung cancer .
    Onametostat
  • HY-107777
    LLY-283
    5+ Cited Publications

    		 Histone Methyltransferase Cancer
    LLY-283, a chemical probe, is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity .
    LLY-283
  • HY-100025A
    HLCL-61 hydrochloride
    2 Publications Verification

    		 Histone Methyltransferase Apoptosis Cancer
    HLCL-61 hydrochloride is a first-in-class inhibitor of protein arginine methyltransferase 5 (PRMT5).
    HLCL-61 hydrochloride
  • HY-111213
    PRMT5-IN-20

    		Histone Methyltransferase Cancer
    PRMT5-IN-20 is a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with anti-tumor activity .
    PRMT5-IN-20
  • HY-109963
    PR5-LL-CM01

    		Histone Methyltransferase Cancer
    PR5-LL-CM01 is a potent protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50= 7.5 μM). Anti-tumor activies .
    PR5-LL-CM01
  • HY-128579
    DW14800

    		Histone Methyltransferase Cancer
    DW14800 is a protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 17 nM. DW14800 reduces H4R3me2s levels and enhances the transcription of HNF4α, but does not alter PRMT5 expression. Anti-cancer activity .
    DW14800
  • HY-Q36691
    PRMT5-IN-30

    		Histone Methyltransferase Cancer
    PRMT5-IN-30 (compound 17) is a potent and selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.33 μM and a Kd of 0.987 μM. PRMT5-IN-30 exhibits a broad selectivity against a panel of other methyltransferases. PRMT5-IN-30 inhibits PRMT5 mediated SmD3 methylation .
    PRMT5-IN-30
  • HY-126256A
    PRMT5-IN-1 hydrochloride

    		Histone Methyltransferase Cancer
    PRMT5 IN-1 hydrochloride (compound 9), a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 11 nM for PRMT5/MEP50. PRMT5 IN-1 hydrochloride can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions .
    PRMT5-IN-1 hydrochloride
  • HY-126256
    PRMT5-IN-1

    		Histone Methyltransferase Cancer
    PRMT5 IN-1, a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 11 nM for PRMT5/MEP50. PRMT5 IN-1 can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions .
    PRMT5-IN-1
  • HY-176534
    PRMT5-IN-52

    		Histone Methyltransferase Cancer
    PRMT5-IN-52 (Compound 17) is a non-nucleoside Protein Arginine Methyltransferase 5 (PRMT5) inhibitor with inhibitory rates of 20.2% at 10 μM. PRMT5-IN-52 has potent antitumor activity, promising for research of cancers, including lung, prostate cancer, and colorectal carcinoma .
    PRMT5-IN-52
  • HY-176701
    PRMT5-MTA-IN-4

    		Histone Methyltransferase Cancer
    PRMT5-MTA-IN-4 (Compound 30) is a potent irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50=8 nM). PRMT5-MTA-IN-4 blocks arginine methylation, inhibiting ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-4 exhibits antiproliferative activity in multiple tumor cell lines (e.g., IC50=0.3 μM in DLD-1 cells). PRMT5-MTA-IN-4 is promising for research of hematological malignancies, such as acute myeloid leukemia, diffuse large B-cell lymphoma .
    PRMT5-MTA-IN-4
  • HY-141875
    PRMT5-IN-13

    		Histone Methyltransferase Cancer
    PRMT5-IN-13 is a selective inhibitor of protein arginine methyltransferase 5 (prmt5).
    PRMT5-IN-13
  • HY-100025
    HLCL-61

    		Histone Methyltransferase Cancer
    HLCL-61 is a first-in-class small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5).
    HLCL-61
  • HY-P3822
    PRMT5-IN-23

    		Histone Methyltransferase Cancer
    PRMT5-IN-23 (compound 50) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .
    PRMT5-IN-23
  • HY-153421
    PRMT5-IN-28

    		Histone Methyltransferase Cancer
    PRMT5-IN-28 (compound 36) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) enzyme. Protein arginine methylation is a common post-translational modification involved in gene transcription, mRNA splicing, DNA repair, protein cellular localization, cell fate determination and signal transduction, etc. Abnormal PRMT5 can promote cancer cell proliferation, resist apoptosis, enhance invasion and metastasis, and affect immune escape .
    PRMT5-IN-28
  • HY-172733
    PRMT5-MTA-IN-3

    		Histone Methyltransferase Cancer
    PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective protein arginine methyltransferase 5 (PRMT5) inhibitor. PRMT5-MTA-IN-3 inhibits cell proliferation in the MTAP-deficient colorectal cancer HCT - 116 cell line with an IC50 value of 5 nM. PRMT5-MTA-IN-3 is promising for research of cancers, especially for MTAP-deficient tumors, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer .
    PRMT5-MTA-IN-3
  • HY-180356
    PRMT5-IN-54

    		Histone Methyltransferase Inflammation/Immunology
    PRMT5-IN-54 (example 92a) is a protein arginine methyltransferase 5 (PRMT5) inhibitor. PRMT5-IN-54 can be used for the study of autoimmune diseases .
    PRMT5-IN-54
  • HY-100025AR
    HLCL-61 hydrochloride (Standard)

    		Histone Methyltransferase Reference Standards Apoptosis Cancer
    HLCL-61 (hydrochloride) (Standard) is the analytical standard of HLCL-61 (hydrochloride) (HY-100025A). This product is intended for research and analytical applications. HLCL-61 hydrochloride is a first-in-class inhibitor of protein arginine methyltransferase 5 (PRMT5).
    HLCL-61 hydrochloride (Standard)
  • HY-101564R
    Onametostat (Standard)

    JNJ-64619178 (Standard)

    		 Histone Methyltransferase Reference Standards Cancer
    Onametostat (Standard) is the analytical standard of Onametostat (HY-101564). This product is intended for research and analytical applications. Onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.14 nM. Onametostat has potent activity in lung cancer .
    Onametostat (Standard)
  • HY-107777R
    LLY-283 (Standard)

    		Reference Standards Histone Methyltransferase Cancer
    LLY-283 (Standard) is the analytical standard of LLY-283 (HY-107777). This product is intended for research and analytical applications. LLY-283, a chemical probe, is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity .
    LLY-283 (Standard)
  • HY-101563R
    GSK3326595 (Standard)

    EPZ015938 (Standard)

    		 Histone Methyltransferase Reference Standards SARS-CoV MDM-2/p53 CDK Apoptosis Infection Cancer
    GSK3326595 (Standard) is the analytical standard of GSK3326595 (HY-101563). This product is intended for research and analytical applications. GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .
    GSK3326595 (Standard)
  • HY-182820
    YZ-836P

    		Histone Methyltransferase PROTACs KLF Cancer
    YZ-836P is a Protein arginine methyltransferase 5 (PRMT5) targeting agent. YZ-836P promotes ubiquitination and proteasomal degradation of PRMT5 in a cereblon (CRBN)-dependent manner, which in turn reduces levels of its downstream target KLF5. YZ-836P induces G1 phase cell cycle arrest in triple-negative breast cancer cells. YZ-836P induces Apoptosis in triple-negative breast cancer cells. YZ-836P exerts cytotoxic effects on triple-negative breast cancer cells. YZ-836P inhibits the growth of triple-negative breast cancer patient-derived organoids. YZ-836P inhibits the growth of triple-negative breast cancer xenografts in nude mice. YZ-836P can be used for the research of triple-negative breast cancer .
    YZ-836P

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: